Fibroblast Growth Factor - 23 (FGF-23) e Cardiorenal Syndrome

Authors

  • Luca Di Lullo U.O.C. Nefrologia e Dialisi, Ospedale “L. Parodi-Delfino”, Colleferro (RM)
  • Rodolfo Rivera Divisione di Nefrologia, Ospedale S. Gerardo, Monza
  • Antonio De Pascalis U.O.C. Nefrologia, Dialisi e Trapianto, Ospedale “V. Fazzi”, Lecce
  • Fulvio Floccari U.O.C. Nefrologia e Dialisi, Ospedale “S. Paolo”, Civitavecchia (RM)
  • Vincenzo Barbera U.O.C. Nefrologia e Dialisi, Ospedale “L. Parodi-Delfino”, Colleferro (RM)
  • Claudio Ronco International Renal Research Institute, Ospedale “S. Bortolo”, Vicenza
  • Alberto Santoboni U.O.C. Nefrologia e Dialisi, Ospedale “L. Parodi-Delfino”, Colleferro (RM)

DOI:

https://doi.org/10.33393/gcnd.2015.781

Keywords:

FGF-23, Chronic kidney disease, Cardiovascular disease, Sevelamer Carbonate, Lanthanum carbonate

Abstract

Several abnormalities in chronic kidney disease-related mineral and bone disease (CKD-MBD) have emerged as novel risk factors in excess cardiovascular mortality in patients with CKD and end-stage renal disease (ESRD). Hyperphosphatemia, vascular calcifications development, and decreased active vitamin D production, leading to activation of the renin angiotensin system (RAS), have been identified as the primary cause of CKD-MBD-associated mortality in CKD. Recently, the fibroblast growth factor-23 (FGF-23), a newly discovered hormone produced in the bone that regulates phosphate and vitamin D metabolism by the kidney, has been reported as a strong predictor of adverse cardiovascular outcomes in patients with CKD and ESRD. The main physiological functions of FGF-23 are mediated by the activation of the FGF receptor/α-klotho co-receptor complexes in target tissues. Elevated FGF-23 has been associated with left ventricular hypertrophy (LVH), and it has been suggested that FGF-23 may induce myocardial hypertrophy through a direct effect on cardiac myocytes. Understanding of FGF-23's pathophysiology and mechanisms of action responsible for its negative effects will be necessary to develop therapeutic strategies to treat CKD-MBD. (Cardionephrology)

Downloads

Download data is not yet available.

Published

2015-03-02

How to Cite

Di Lullo, L., Rivera, R., De Pascalis, A., Floccari, F., Barbera, V., Ronco, C., & Santoboni, A. (2015). Fibroblast Growth Factor - 23 (FGF-23) e Cardiorenal Syndrome. Giornale Di Clinica Nefrologica E Dialisi, 27(1), 23–28. https://doi.org/10.33393/gcnd.2015.781

Issue

Section

Cardionephrology

Metrics